160 related articles for article (PubMed ID: 37442659)
1. Fathoming the Role of Semaglutide in Obesity Therapeutics.
George M; Balachandran K; Jinson J
Clin Ther; 2023 Aug; 45(8):804-805. PubMed ID: 37442659
[No Abstract] [Full Text] [Related]
2. Oral semaglutide (Rybelsus) for type 2 diabetes.
Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
[No Abstract] [Full Text] [Related]
3. Semaglutide: First Global Approval.
Dhillon S
Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide: new dawn for diabetics.
Memon A; Tehrim M; Kumari B
J Pak Med Assoc; 2023 Mar; 73(3):721. PubMed ID: 36932797
[No Abstract] [Full Text] [Related]
5. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
Scheen AJ
Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
[No Abstract] [Full Text] [Related]
6. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
Basolo A; Fierabracci P; Salvetti G; Santini F
J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
8. Once-Weekly Semaglutide in Adolescents with Obesity.
Malozowski S
N Engl J Med; 2023 Mar; 388(12):1145-1146. PubMed ID: 36947475
[No Abstract] [Full Text] [Related]
9. Once-Weekly Semaglutide in Adolescents with Obesity.
Snaith JR; Greenfield JR
N Engl J Med; 2023 Mar; 388(12):1145. PubMed ID: 36947474
[No Abstract] [Full Text] [Related]
10. Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
Weghuber D; Kelly AS; Arslanian S
N Engl J Med; 2023 Mar; 388(12):1146. PubMed ID: 36947476
[No Abstract] [Full Text] [Related]
11. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
Villela R; Correa R
J Investig Med; 2022 Jan; 70(1):3-4. PubMed ID: 34949728
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
13. [The glucagon-like peptide-1 receptor-agonist semaglutide].
Boje AD; Juhl CR; Torekov SS; Madsbad S
Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
[TBL] [Abstract][Full Text] [Related]
14. Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
Kyrillos JV; O'Neil PM; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):1-4. PubMed ID: 36691310
[No Abstract] [Full Text] [Related]
15. Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese.
Slawson DC
Am Fam Physician; 2021 Jul; 104(1):96-97. PubMed ID: 34264618
[No Abstract] [Full Text] [Related]
16. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
Blakely KK; Weaver K
Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
[TBL] [Abstract][Full Text] [Related]
17. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM; Wilson SA
Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
[No Abstract] [Full Text] [Related]
18. Efficacy of semaglutide versus liraglutide in clinical practice.
Goncalves E; Bell DS
Diabetes Metab; 2020 Nov; 46(6):515-517. PubMed ID: 31606525
[No Abstract] [Full Text] [Related]
19. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
Kalra S; Kalhan A; Berard L
Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
[No Abstract] [Full Text] [Related]
20. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Kushner RF; Calanna S; Davies M; Dicker D; Garvey WT; Goldman B; Lingvay I; Thomsen M; Wadden TA; Wharton S; Wilding JPH; Rubino D
Obesity (Silver Spring); 2020 Jun; 28(6):1050-1061. PubMed ID: 32441473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]